March 31, 2008
Urodynamix Technologies Receives ISO 13485 Certification
VANCOUVER, British Columbia, March 31, 2008 - Urodynamix Technologies Ltd. (TSX-V:URO) announced today that its Quality Management System, which covers the design and development of medical devices based on near-infrared spectroscopy (NIRS), has met the requirements of the ISO 13485:2003 standard. This certification was obtained following a successful audit in February 2008 by Intertek Testing Services NA Ltd.
“ISO accreditation is a significant achievement for Urodynamix and reflects our commitment to excellent performance in both our internal manufacturing and OEM business,” said Barry Allen, President and CEO of Urodynamix. “The successful implementation of our quality management system will facilitate regulatory approvals of our products on a global basis.”
About ISO Standards
The ISO 13485:2003 is an internationally recognized medical device quality management system (QMS) standard developed by the International Organization for Standardization (ISO). To meet the certification requirements, companies must implement and document QMS processes involving staff training, product design and processes, materials and services purchasing, and product and services delivery.
About Urodynamix Technologies Ltd.
Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix’s breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.
Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Craig Pamplin, PhD, CFA
Director, Corporate Development and Communications
Urodynamix Technologies Ltd.
Tel: (604) 638-0247
Email: cpamplin@urodynamix.com
www.urodynamix.com |
